Fusion Pharmaceuticals, part of the AstraZeneca Group, is redefining precision oncology with next‑generation radioconjugates that deliver powerful alpha‑emitting payloads directly to tumors. Our pipeline spans multiple first‑in‑class programs, backed by a GMP‑compliant, state‑of‑the‑art radiopharmaceutical facility in Hamilton. Join us at the forefront of radiopharma innovation and be part of turning breakthrough science into meaningful outcomes for patients. Note: This role is 5 days per week onsite. The Role As an Associate Director, RC Discovery – Immunohistochemistry (IHC), you will be a recognized expert spearheading the advancement of innovative IHC methodologies for non‑clinical radioconjugate discovery projects in oncology. You will provide critical technical expertise, lead projects, evaluate and interpret complex data, and directly influence go/no‑go decisions for new compounds. A key focus will be driving the integration and implementation of cutting‑edge IHC technologies, multiplexing strategies, and digital pathology solutions to enhance target validation, pharmacodynamics, and biomarker discovery. This new role within RC Discovery Biology involves building and leading a small team. Responsibilities Advance and apply immunohistochemistry (IHC) and/or histopathology expertise, leading projects focused on innovative IHC methodologies. Manage a small team and provide technical expertise in IHC, H&E staining, and autoradiography, ensuring high‑quality data generation. Contribute as a valued expert in IHC to assess target engagement, pharmacodynamic responses, and biomarker identification, influencing critical go/no‑go decisions for new compounds. Oversee the development of innovative projects and provide expert advice on IHC assay design, interpreting complex histopathological and quantitative IHC data, and making high‑level recommendations to resolve issues and advance RC discovery programs. Lead and champion new innovations, including the evaluation, development, and implementation of novel IHC technologies, multiplexing strategies, and digital pathology solutions. Design and implement improvements in IHC technologies, staining protocols, image analysis algorithms, and scientific approaches to enhance the quality, efficiency, and effectiveness of biomarker discovery and target validation. Serve as a primary resource for advanced IHC expertise, sharing knowledge and best practices cross‑functionally, and communicating important initiatives to the team. Collaborate with other functions and ensure clear communication between teams. Provide significant input into performance management of team members, including goal setting and overseeing professional development. Ensure compliance with Good Laboratory Standards (GLS), Safety, Health and Environment (SHE) standards, Radiation Safety, and all relevant internal AstraZeneca standards and external regulations. Essential Qualifications Master’s degree in a relevant discipline. Significant experience in Immunohistochemistry (IHC) and histopathology, including assay development, optimization, validation, digital pathology, and quantitative image analysis within a drug discovery or translational research setting. Proven understanding of molecular and cellular biology. Strong cross‑functional collaboration skills. Desirable PhD degree in a related field and/or professional certification. Specific experience in oncology and radioconjugate discovery research. Benefits & Compensation Annual base salary ranges from 131,201.60 to 172,202.10. In addition, permanent positions offer an annual Variable Pay Bonus/Short Term Incentive opportunity and eligibility to participate in an equity‑based long‑term incentive program (if applicable). Benefits include a competitive Flex Benefits & Retirement Savings Program, 4 weeks of paid vacation, and annual Personal Days. Fixed‑Term Contract/Temporary positions (excluding students) are offered a Contract Benefits Program. AstraZeneca is an equal opportunity employer that is committed to diversity and inclusion and providing a workplace that is free from discrimination. AstraZeneca is committed to accommodating persons with disabilities. Such accommodation is available on request in respect of all aspects of the recruitment, assessment and selection process and may be requested by emailing #J-18808-Ljbffr